GILEAD SCIENCES, INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
GILEAD SCIENCES, INC. (GILD) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of -$599.00 million for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-04.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2015-11-04
- GILEAD SCIENCES, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2015-09-30 was -$91.00M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month |
|---|---|---|---|
| 2015-09-30 | -$91.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | -$599.00M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | -$508.00M 10-Q · filed 2015-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |